| 摘要 |
<p>This disclosure relates to the use of anti-α-synuclein antibody to diagnose an elevated level ofα-synuclein in the brain. Specifically, the disclosure relates to the method of assessing the levels ofα-synuclein in a blood plasma or CSF following administration to the test subject of an anti-α-synuclein antibody or antigen-binding fragment thereof, which can bindα-synuclein with sufficient activity to alter the net efflux ofα-synuclein from brain to blood, or from brain to CSF.</p> |
